FR18C1029I1 - - Google Patents

Info

Publication number
FR18C1029I1
FR18C1029I1 FR18C1029C FR18C1029I1 FR 18C1029 I1 FR18C1029 I1 FR 18C1029I1 FR 18C1029 C FR18C1029 C FR 18C1029C FR 18C1029 I1 FR18C1029 I1 FR 18C1029I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR18C1029I1 publication Critical patent/FR18C1029I1/fr
Application granted granted Critical
Publication of FR18C1029I2 publication Critical patent/FR18C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR18C1029C 2003-05-02 2018-07-06 Dihydroquinazolines substituees a proprietes antivirales Active FR18C1029I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline
PCT/EP2004/004103 WO2004096778A1 (fr) 2003-05-02 2004-04-17 Dihydroquinazolines substituees a proprietes antivirales

Publications (2)

Publication Number Publication Date
FR18C1029I1 true FR18C1029I1 (fr) 2018-08-17
FR18C1029I2 FR18C1029I2 (fr) 2020-07-17

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1029C Active FR18C1029I2 (fr) 2003-05-02 2018-07-06 Dihydroquinazolines substituees a proprietes antivirales

Country Status (39)

Country Link
US (4) US7196086B2 (fr)
EP (1) EP1622880B3 (fr)
JP (1) JP4733631B2 (fr)
KR (1) KR100927063B1 (fr)
CN (1) CN100393706C (fr)
AR (1) AR044078A1 (fr)
AT (1) ATE355280T1 (fr)
AU (1) AU2004233978B2 (fr)
BR (1) BRPI0410029B8 (fr)
CA (1) CA2524069C (fr)
CL (1) CL2004000930A1 (fr)
CO (1) CO5700764A2 (fr)
CY (2) CY1106476T1 (fr)
DE (2) DE10319612A1 (fr)
DK (1) DK1622880T6 (fr)
EC (1) ECSP056138A (fr)
EG (1) EG25273A (fr)
ES (1) ES2284007T7 (fr)
FR (1) FR18C1029I2 (fr)
HK (1) HK1092463A1 (fr)
HN (1) HN2004000146A (fr)
HU (2) HUS1800018I1 (fr)
IL (1) IL171513A (fr)
MA (1) MA27794A1 (fr)
MX (1) MXPA05011707A (fr)
MY (1) MY144616A (fr)
NL (1) NL300933I2 (fr)
NO (2) NO333265B3 (fr)
NZ (1) NZ543317A (fr)
PE (1) PE20050145A1 (fr)
PL (1) PL1622880T6 (fr)
PT (1) PT1622880E (fr)
RU (1) RU2360912C2 (fr)
SI (1) SI1622880T1 (fr)
TW (1) TWI335912B (fr)
UA (1) UA82519C2 (fr)
UY (1) UY28294A1 (fr)
WO (1) WO2004096778A1 (fr)
ZA (1) ZA200508710B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
CA2916143C (fr) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Letermovir amorphe et formulations pharmaceutiques solides destinees a etre administrees par voie orale le comprenant
WO2015088931A1 (fr) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Procédé de préparation de composés quinazoline substitués
WO2017091453A1 (fr) * 2015-11-24 2017-06-01 Merck Sharp & Dohme Corp. Nouveaux procédés de production de composés de quinazoline substitués à l'aide de catalyseurs de liaison hydrogène
CN109476677B (zh) 2016-08-08 2024-06-07 辉诺生物医药科技(杭州)有限公司 抗hcmv病毒化合物
US11174270B2 (en) 2018-02-08 2021-11-16 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
EP3527209A1 (fr) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Dérivés pharmaceutiques de noyau hétérobicyclique 6,5
CN112996789A (zh) 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
AR121440A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales
AR121438A1 (es) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
AR121437A1 (es) * 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético
UY39096A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
EP3906929A1 (fr) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir pour son utilisation dans la prévention et le traitement des infections à coronavirus
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2023185597A1 (fr) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 Intermédiaire de letermovir et son procédé de préparation
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
ES2252455T3 (es) 2001-04-19 2006-05-16 Bayer Healthcare Ag Arilsulfonamidas como agentes antivirales.
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 T-형 칼슘 채널 차단제로서 유용한 3,4-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
JP5139083B2 (ja) * 2005-01-25 2013-02-06 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 抗腫瘍剤としてのキノキサリン誘導体
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
ATE449097T1 (de) 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
CA2916143C (fr) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Letermovir amorphe et formulations pharmaceutiques solides destinees a etre administrees par voie orale le comprenant

Also Published As

Publication number Publication date
NO333265B3 (no) 2019-06-03
DE10319612A1 (de) 2004-11-18
EP1622880B3 (fr) 2018-05-23
WO2004096778A1 (fr) 2004-11-11
ZA200508710B (en) 2006-12-27
KR100927063B1 (ko) 2009-11-13
ES2284007T3 (es) 2007-11-01
HUS1800028I1 (hu) 2018-07-30
US20070191387A1 (en) 2007-08-16
DK1622880T3 (da) 2007-06-25
EP1622880B1 (fr) 2007-02-28
CY2018019I1 (el) 2018-12-12
CN1784390A (zh) 2006-06-07
CY1106476T1 (el) 2012-01-25
NO2018022I1 (no) 2018-07-04
NZ543317A (en) 2008-05-30
CN100393706C (zh) 2008-06-11
BRPI0410029A (pt) 2006-04-25
AU2004233978B2 (en) 2010-02-11
PL1622880T6 (pl) 2018-08-31
PT1622880E (pt) 2007-06-04
BRPI0410029B1 (pt) 2019-12-31
USRE46791E1 (en) 2018-04-17
NO20055649L (no) 2006-01-31
HK1092463A1 (en) 2007-02-09
RU2005137276A (ru) 2006-07-27
HN2004000146A (es) 2008-06-24
MA27794A1 (fr) 2006-03-01
HUS1800018I1 (hu) 2018-05-28
CL2004000930A1 (es) 2005-03-18
FR18C1029I2 (fr) 2020-07-17
KR20060009883A (ko) 2006-02-01
ES2284007T7 (es) 2018-06-20
CA2524069A1 (fr) 2004-11-11
BRPI0410029B8 (pt) 2021-06-15
MY144616A (en) 2011-10-14
USRE49698E1 (en) 2023-10-17
JP4733631B2 (ja) 2011-07-27
NO20055649D0 (no) 2005-11-30
US7196086B2 (en) 2007-03-27
CA2524069C (fr) 2011-11-08
ATE355280T1 (de) 2006-03-15
EG25273A (en) 2011-12-04
DK1622880T6 (da) 2018-06-18
UY28294A1 (es) 2004-11-30
CO5700764A2 (es) 2006-11-30
AR044078A1 (es) 2005-08-24
AU2004233978A1 (en) 2004-11-11
MXPA05011707A (es) 2006-02-13
ECSP056138A (es) 2006-04-19
US8513255B2 (en) 2013-08-20
RU2360912C2 (ru) 2009-07-10
PE20050145A1 (es) 2005-05-22
SI1622880T1 (sl) 2007-08-31
TWI335912B (en) 2011-01-11
EP1622880A1 (fr) 2006-02-08
TW200510343A (en) 2005-03-16
UA82519C2 (uk) 2008-04-25
NO333265B1 (no) 2013-04-22
NL300933I2 (nl) 2018-04-26
PL1622880T3 (pl) 2007-08-31
DE502004003052D1 (de) 2007-04-12
IL171513A (en) 2011-11-30
US20050065160A1 (en) 2005-03-24
JP2006525249A (ja) 2006-11-09
CY2018019I2 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
BE2015C007I2 (fr)
BE2014C055I2 (fr)
BE2014C027I2 (fr)
BE2014C003I2 (fr)
BE2013C075I2 (fr)
BE2013C070I2 (fr)
BE2013C067I2 (fr)
BE2013C038I2 (fr)
BE2013C036I2 (fr)
BE2011C030I2 (fr)
BE2015C005I2 (fr)
BE2012C053I2 (fr)
AU2002316511A1 (fr)
AU2002359010A1 (fr)
AU2002324323A1 (fr)
AU2002327042A1 (fr)
AU2002327736A1 (fr)
AU2002329412A1 (fr)
AU2002331433A1 (fr)
AU2002332887A1 (fr)
AU2002333044A1 (fr)
AU2002337949A1 (fr)
AU2002339901A1 (fr)
AU2002340206A1 (fr)
AU2002348177A1 (fr)